IL‐6 in inflammation, immunity, and disease
Open accessAbstract
Interleukin 6 (IL-6), promptly and transiently produced in response to infections and tissue injuries, contributes to host defense through the stimulation of acute phase responses, hematopoiesis, and immune reactions. Although its expression is strictly controlled by transcriptional and posttranscriptional mechanisms, dysregulated continual synthesis of IL-6 plays a pathological effect on chronic inflammation and autoimmunity. For this reason, tocilizumab, a humanized anti-IL-6 receptor antibody was developed. Various clinical trials have since shown the exceptional efficacy of tocilizumab, which resulted in its approval for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. Moreover, tocilizumab is expected to be effective for other intractable immune-mediated diseases. In this context, the mechanism for the continual synthesis of IL-6 needs to be elucidated to facilitate the development of more specific therapeutic approaches and analysis of the pathogenesis of specific diseases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
gp130 is shared by the IL-6 cytokine family consisting of IL-6, IL-11, CNF, LIF, OSM, CT-1, CLCF1, and IL-27.
“As a beta‐receptor, gp130 is shared by the IL‐6 cytokine family consisting of IL‐6, IL‐11, CNF, LIF, OSM, CT‐1, CLCF1, and IL‐27. 37”
From Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting (2022) · cites this paper as [37]
The IL-6 receptor-mediated signaling section says gp130 is the signal-transducing chain shared by the listed IL-6-family cytokines. However, the source also includes IL-35, which the citing sentence omits from its apparently exhaustive list. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · see citing works
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145 · see citing works
Circulating mitochondrial DAMPs cause inflammatory responses to injury
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., & Hauser, C. J. (2010) · Nature · doi:10.1038/nature08780 · Cited by 3,812 · see citing works
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1× · see citing works
“As for serum iron, IL-6 induces hepcidin production, which blocks the action of iron transporter ferroportin 1 on gut and, thus, reduces serum iron levels (Nemeth et al. 2004).”
BackgroundAU-rich elements: characterization and importance in mRNA degradation
Chen, C.-Y. A., & Shyu, A.-B. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89102-1 · Cited by 1,948 · see citing works
Imai, Y., Kuba, K., Neely, G. G., Yaghubian-Malhami, R., Perkmann, T., van Loo, G., Ermolaeva, M., Veldhuizen, R., Leung, Y. H. C., Wang, H., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.043 · Cited by 1,356 · see citing works
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089 · see citing works
Stumhofer, J. S., Laurence, A., Wilson, E. H., Huang, E., Tato, C. M., Johnson, L. M., Villarino, A. V., Huang, Q., Yoshimura, A., Sehy, D., et al. (2006) · Nature Immunology · doi:10.1038/ni1376 · Cited by 955 · see citing works
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928 · cited 3× · see citing works
“…have shown that dysregulation of IL-6 production occurs in the synovial cells of RA (Hirano et al. 1988), swollen lymph nodes of Castleman’s disease (Yoshizaki et al. 1989), myeloma cells (Kawano et al. 1988), and peripheral blood cells or involved tissues in various other autoimmune and chronic…”
BackgroundSchmitz, J., Weissenbach, M., Haan, S., Heinrich, P. C., & Schaper, F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12848 · Cited by 388 · cited 2× · see citing works
“In this context, SOCS1 binds to tyrosine-phosphorylated JAK (Naka et al. 1997), whereas SOCS3 binds to tyrosine-phosphorylated gp130 (Schmitz et al. 2000) to stop IL-6 signaling by means of a negative feedback loop.”
BackgroundHirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki, F., Shimizu, M., Murashima, A., Tsunasawa, S., & Sakiyama, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.228 · Cited by 351 · see citing works
Katsume, A., Saito, H., Yamada, Y., Yorozu, K., Ueda, O., Akamatsu, K.-I., Nishimoto, N., Kishimoto, T., Yoshizaki, K., & Ohsugi, Y. (2002) · Cytokine · doi:10.1006/cyto.2002.2012 · Cited by 134 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 5
- Hashizume M, Hayakawa N, Mihara M. 2008. IL-6 trans- signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-a and IL-17. Rheumatology (Oxford) 47: 1635- 1640.
- Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, Ornetti P, Maillefert JF, Miossec P, Bonnotte B. 2012. Brief report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheu- matoid arthritis. Arthritis Rheum 64: 2499-2503. IL-6 in Inflammation, Immunity, and Disease Cite this article as Cold Spring Harb Perspect Biol 2014;6:a016295
- Tanaka T, Hagihara K, Hishitani Y, Ogata A. 2011. Tocilizu- mab for the treatment of AA amyloidosis. In Amyloid- osis-An insight to disease of systems and novel therapies (ed. Isil Adadan Guvenc MD), pp. 155-170. InTech Open Access, Rijeka, Croatia.
- Tanaka T, Ogata A, Narazaki M. 2013. Tocilizumab: An up- dated review of its use in the treatment of rheumatoid arthritis and its application for other immune-mediated diseases. Clin Med Insights Ther 5: 33-52.
- Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheo- dorou A, Sfikakis PP. 2011. Early effects of IL-6 receptor inhibition on bone homeostasis: A pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol 29: 921- 925.
Cited by
Sorted by citations
Gut-microbiota-targeted diets modulate human immune status
Wastyk, H. C., Fragiadakis, G. K., Perelman, D., Dahan, D., Merrill, B. D., Yu, F. B., Topf, M., Gonzalez, C. G., Van Treuren, W., Han, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.019 · Cited by 1,385 · see citing works
Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., & Wen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01708 · Cited by 1,094 · see citing works
Unmasking senescence: context-dependent effects of SASP in cancer
Faget, D. V., Ren, Q., & Stewart, S. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0156-2 · Cited by 863 · see citing works
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 870 · see citing works
Self-citationMaeda, Y., Kurakawa, T., Umemoto, E., Motooka, D., Ito, Y., Gotoh, K., Hirota, K., Matsushita, M., Furuta, Y., Narazaki, M., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39783 · Cited by 686 · see citing works
Self-citationNdeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678 · see citing works
Senescent cell clearance by the immune system: Emerging therapeutic opportunities
Prata, L. G. P. L., Ovsyannikova, I. G., Tchkonia, T., & Kirkland, J. L. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2019.04.003 · Cited by 497 · see citing works
The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019
Liu, T., Zhang, J., Yang, Y., Ma, H., Li, Z., Zhang, J., Cheng, J., Zhang, X., Zhao, Y., Xia, Z., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012421 · Cited by 498 · see citing works
Veiga, V. C., Prats, J. A. G. G., Farias, D. L. C., Rosa, R. G., Dourado, L. K., Zampieri, F. G., Machado, F. R., Lopes, R. D., Berwanger, O., Azevedo, L. C. P., et al. (2021) · BMJ · doi:10.1136/bmj.n84 · Cited by 388 · see citing works
Interleukin 6 as an Energy Allocator in Muscle Tissue
Kistner, T. M., Pedersen, B. K., & Lieberman, D. E. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00538-4 · Cited by 295 · see citing works
Cheng, S.-C., Huang, W.-C., S. Pang, J.-H., Wu, Y.-H., & Cheng, C.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122957 · Cited by 235 · see citing works
Regulation of IL-6 in Immunity and Diseases
Tanaka, T., Narazaki, M., Masuda, K., & Kishimoto, T. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-024-0921-5_4 · Cited by 235 · see citing works
Self-citationSepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting
Zanders, L., Kny, M., Hahn, A., Schmidt, S., Wundersitz, S., Todiras, M., Lahmann, I., Bandyopadhyay, A., Wollersheim, T., Kaderali, L., et al. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12867 · Cited by 225 · see citing works
“As a beta-receptor, gp130 is shared by the IL-6 cytokine family consisting of IL-6, IL-11, CNF, LIF, OSM, CT-1, CLCF1, and IL27.”
BackgroundHost–microbiota interactions in rheumatoid arthritis
Maeda, Y., & Takeda, K. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0283-6 · Cited by 180 · see citing works
Reeh, H., Rudolph, N., Billing, U., Christen, H., Streif, S., Bullinger, E., Schliemann-Bullinger, M., Findeisen, R., Schaper, F., Huber, H. J., et al. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0356-0 · Cited by 180 · see citing works
Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
Kim, S. T., Tayar, J., Trinh, V. A., Suarez-Almazor, M., Garcia, S., Hwu, P., Johnson, D. H., Uemura, M., & Diab, A. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211560 · Cited by 170 · see citing works
Galland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165 · see citing works
Role of Interleukin-6 in Vascular Health and Disease
Villar-Fincheira, P., Sanhueza-Olivares, F., Norambuena-Soto, I., Cancino-Arenas, N., Hernandez-Vargas, F., Troncoso, R., Gabrielli, L., & Chiong, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.641734 · Cited by 154 · see citing works
Harbour, S. N., DiToro, D. F., Witte, S. J., Zindl, C. L., Gao, M., Schoeb, T. R., Jones, G. W., Jones, S. A., Hatton, R. D., & Weaver, C. T. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaw2262 · Cited by 151 · see citing works
“IL-6 is produced by a wide range of cells, including hematopoieticderived monocytes, macrophages, and dendritic cells, and nonhematopoietic stromal cells such as fibroblasts and endothelial cells (28).”
BackgroundThacker, V. V., Sharma, K., Dhar, N., Mancini, G.-F., Sordet-Dessimoz, J., & McKinney, J. D. (2021) · The EMBO Reports · doi:10.15252/embr.202152744 · Cited by 142 · see citing works
IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140 · see citing works
Self-citationJeppesen, R., Christensen, R. H. B., Pedersen, E. M. J., Nordentoft, M., Hjorthøj, C., Köhler-Forsberg, O., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.08.028 · Cited by 132 · see citing works
IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease
Park, J., Zhao, Y., Zhang, F., Zhang, S., Kwong, A. C., Zhang, Y., Hoffmann, H.-H., Bushweller, L., Wu, X., Ashbrook, A. W., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.022 · Cited by 138 · see citing works
Inoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133 · see citing works
Tran, N., Zhebrak, M., Yacoub, C., Pelletier, J., & Hawley, D. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.043 · Cited by 104 · see citing works
Biomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102 · see citing works
van der Willik, K. D., Fani, L., Rizopoulos, D., Licher, S., Fest, J., Schagen, S. B., Ikram, M. K., & Ikram, M. A. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1454-z · Cited by 96 · see citing works
Tumor-associated macrophage polarization in the inflammatory tumor microenvironment
Zou, Z., Lin, H., Li, M., & Lin, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1103149 · Cited by 100 · see citing works
Chainoglou, E., & Hadjipavlou-Litina, D. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1614560 · Cited by 92 · see citing works
Nan, L., Guo, P., Hui, W., Xia, F., & Yi, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1592596 · Cited by 84 · see citing works
Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation
Barchetta, I., Cimini, F. A., Ciccarelli, G., Baroni, M. G., & Cavallo, M. G. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01052-3 · Cited by 77 · see citing works
The implications of bone marrow adipose tissue on inflammaging
Aaron, N., Costa, S., Rosen, C. J., & Qiang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.853765 · Cited by 74 · see citing works
Naseem, S., Hussain, T., & Manzoor, S. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.01.002 · Cited by 72 · see citing works
Potential Impact of Prosthetic Biomaterials on the Periodontium: A Comprehensive Review
Alarcón-Sánchez, M. A., Heboyan, A., Fernandes, G. V. D. O., Castro-Alarcón, N., & Romero-Castro, N. S. (2023) · Molecules · doi:10.3390/molecules28031075 · Cited by 52 · see citing works
Casaletto, K. B., Staffaroni, A. M., Elahi, F., Fox, E., Crittenden, P. A., You, M., Neuhaus, J., Glymour, M., Bettcher, B. M., Yaffe, K., et al. (2018) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.05.004 · Cited by 47 · see citing works
Investigating Immunomodulatory Biomaterials for Preventing the Foreign Body Response
Kim, A., Downer, M. A., Berry, C. E., Valencia, C., Fazilat, A. Z., & Griffin, M. (2023) · Bioengineering · doi:10.3390/bioengineering10121411 · Cited by 38 · see citing works
Laval, K., Van Cleemput, J., Vernejoul, J. B., & Enquist, L. W. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008087 · Cited by 36 · see citing works
Impact of Age-, Cancer- and Treatment-Driven Inflammation on T Cell Function and Immunotherapy
Quinn, K. M., Kartikasari, A. E. R., Cooke, R. E., Koldej, R. M., Ritchie, D. S., & Plebanski, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0520-466r · Cited by 31 · see citing works
Therapeutic Potential and Predictive Pharmaceutical Modeling of Stilbenes in Cannabis sativa
O’Croinin, C., Garcia Guerra, A., Doschak, M. R., Löbenberg, R., & Davies, N. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071941 · Cited by 25 · see citing works
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20 · see citing works
Development and evaluation of IL‐6 overexpressing mesenchymal stem cells (MSCs)
Huang, P., Zhang, C., Delawary, M., Korchak, J. A., Suda, K., & Zubair, A. C. (2022) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3274 · Cited by 15 · see citing works
Huang, S. U.-S., & O’Sullivan, K. M. (2022) · doi:10.20944/preprints202203.0021.v1 · Cited by 65 · see citing works
Supasitthumrong, T., Tunvirachaisakul, C., Aniwattanapong, D., Tangwongchai, S., Chuchuen, P., Tawankanjanachot, I., Snabboon, T., Hemrungrojn, S., Carvalho, A. F., & Maes, M. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190114 · Cited by 13 · see citing works
Role of inflammation in short sleep duration across childhood and psychosis in young adulthood
Morales-Muñoz, I., Marwaha, S., Upthegrove, R., & Cropley, V. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.0796 · Cited by 13 · see citing works
Trinh, B., Peletier, M., Simonsen, C., Plomgaard, P., Karstoft, K., Pedersen, B. K., van Hall, G., & Ellingsgaard, H. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac239 · Cited by 7 · see citing works
Saha, D., Dutta, P., & Chakraborty, A. (2025) · Immuno · doi:10.3390/immuno5040045 · Cited by 3 · see citing works
CDK8 fine-tunes IL-6 transcriptional activities by limiting STAT3 resident time at the gene loci
Martinez-Fabregas, J., Wang, L., Pohler, E., Cozzani, A., Kazemian, M., Mitra, S., & Moraga, I. (2020) · doi:10.1101/2020.03.19.998351 · Cited by 2 · see citing works
- Authors
- Tanaka, T., Narazaki, M., & Kishimoto, T.
- Affiliations
- Immunology Frontier Research Center, The University of Osaka (JP)
- The University of Osaka (JP)
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-09-04
- Volume
- 6
- Issue
- 10
- Pages
- a016295-a016295
- ISSN
- 1943-0264 (ISSN-L)
- PMC
- PMC4176007
- OpenAlex
- W2148658155
- Cited by
- 5,046
- References
- 12
- Citations by year
- 2026: 519 · 2025: 703 · 2024: 732 · 2023: 693 · 2022: 682 · 2021: 652 · 2020: 522 · 2019: 256 · 2018: 156 · 2017: 63 · 2016: 41 · 2015: 22 · 2014: 1
- Type
- posted content
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- Cold Spring Harbor Perspectives in Biology (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chugai Pharmaceutical
- Topics
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- interleukin-6, chronic inflammation, autoimmunity, tocilizumab, anti-IL-6 receptor antibody, rheumatoid arthritis, juvenile idiopathic arthritis, acute phase response, hematopoiesis, post-transcriptional regulation, immune-mediated diseases
- MeSH terms
- Gene Expression Regulation, Humans, Inflammation, Signal Transduction, Interleukin-6, Receptors, Aryl Hydrocarbon, Models, Immunological, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
